Adicet Bio, Inc.
ACETNASDAQHealthcare● Active
$7.22
$-0.04(-0.55%)
Market Cap$67494293
P/E Ratio—
52W High$17.44
52W Low$6.01
Adicet Bio, Inc. (ACET) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
ACET · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2026Report Date: May 13, 2026EPS Actual
-$1.88
Est. -$2.93 · +35.8%
Revenue
—
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 13, 2026
After Market Close
▲ Beat EPS✓ 2-Quarter EPS Beat Streak
ACET reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.02
Rev. $0.33B
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.02
Rev. Est.$0.33B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 6, 2026 | -$2.18 | — | — | — | — | — |
| ▲ Q2 FY2026 | May 13, 2026 | -$2.93 | -$1.88 | +35.8% | — | — | — |
| ▲ Q1 FY2026 | Mar 12, 2026 | -$3.23 | -$2.94 | +9.0% | — | $0.00B | — |
| ▼ Q4 FY2025 | Nov 5, 2025 | -$4.16 | -$4.64 | -11.5% | — | — | — |
| ▼ Q3 FY2025 | Aug 7, 2025 | -$5.12 | -$5.44 | -6.3% | — | — | — |
| ▲ Q2 FY2025 | May 6, 2025 | -$5.44 | -$4.96 | +8.8% | — | — | — |
| ▲ Q1 FY2025 | Mar 6, 2025 | -$5.92 | -$5.12 | +13.5% | — | — | — |
| ▲ Q4 FY2024 | Nov 6, 2024 | -$5.76 | -$5.44 | +5.6% | — | — | — |
Q3 FY2026
Aug 6, 2026
EPS Actual
—
EPS Est.
-$2.18
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 13, 2026Beat
EPS Actual
-$1.88
EPS Est.
-$2.93
EPS Surpr.
+35.8%
Revenue
—
Q1 FY2026
Mar 12, 2026Beat
EPS Actual
-$2.94
EPS Est.
-$3.23
EPS Surpr.
+9.0%
Revenue
—
Q4 FY2025
Nov 5, 2025Miss
EPS Actual
-$4.64
EPS Est.
-$4.16
EPS Surpr.
-11.5%
Revenue
—
Q3 FY2025
Aug 7, 2025Miss
EPS Actual
-$5.44
EPS Est.
-$5.12
EPS Surpr.
-6.3%
Revenue
—
Q2 FY2025
May 6, 2025Beat
EPS Actual
-$4.96
EPS Est.
-$5.44
EPS Surpr.
+8.8%
Revenue
—
Q1 FY2025
Mar 6, 2025Beat
EPS Actual
-$5.12
EPS Est.
-$5.92
EPS Surpr.
+13.5%
Revenue
—
Q4 FY2024
Nov 6, 2024Beat
EPS Actual
-$5.44
EPS Est.
-$5.76
EPS Surpr.
+5.6%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $-1.23 | $-1.23 | $-1.23 | 1 |
| Q3 FY2027 | $-1.21 | $-1.21 | $-1.21 | 1 |
| Q2 FY2027 | $-1.38 | $-1.38 | $-1.38 | 1 |
| Q1 FY2027 | $-1.37 | $-1.37 | $-1.37 | 1 |
| Q4 FY2026 | $-1.66 | $-1.66 | $-1.66 | 1 |
| Q3 FY2026 | $-2.78 | $-1.93 | $-1.06 | 3 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 13, 2026 | +35.8% | $7.95 | $8.07 | +1.51% |
| ▲ Q1 FY2026 | Mar 12, 2026 | +9.0% | $7.47 | $7.04 | -5.76% |
| ▼ Q4 FY2025 | Nov 5, 2025 | -11.5% | $11.04 | $11.04 | +0.00% |
| ▼ Q3 FY2025 | Aug 7, 2025 | -6.3% | $11.21 | $10.99 | -1.96% |
| ▲ Q2 FY2025 | May 6, 2025 | +8.8% | $10.65 | $9.64 | -9.48% |
| ▲ Q1 FY2025 | Mar 6, 2025 | +13.5% | $14.00 | $13.54 | -3.29% |
| ▲ Q4 FY2024 | Nov 6, 2024 | +5.6% | $20.96 | $20.80 | -0.76% |
| ▲ Q3 FY2024 | Aug 13, 2024 | +5.7% | $20.32 | $20.80 | +2.36% |
Q2 FY2026+1.51%
Report Date
May 13, 2026
EPS Beat/Miss
+35.8%
Price Before
$7.95
Price After
$8.07
Q1 FY2026-5.76%
Report Date
Mar 12, 2026
EPS Beat/Miss
+9.0%
Price Before
$7.47
Price After
$7.04
Q4 FY2025+0.00%
Report Date
Nov 5, 2025
EPS Beat/Miss
-11.5%
Price Before
$11.04
Price After
$11.04
Q3 FY2025-1.96%
Report Date
Aug 7, 2025
EPS Beat/Miss
-6.3%
Price Before
$11.21
Price After
$10.99
Q2 FY2025-9.48%
Report Date
May 6, 2025
EPS Beat/Miss
+8.8%
Price Before
$10.65
Price After
$9.64
Q1 FY2025-3.29%
Report Date
Mar 6, 2025
EPS Beat/Miss
+13.5%
Price Before
$14.00
Price After
$13.54
Q4 FY2024-0.76%
Report Date
Nov 6, 2024
EPS Beat/Miss
+5.6%
Price Before
$20.96
Price After
$20.80
Q3 FY2024+2.36%
Report Date
Aug 13, 2024
EPS Beat/Miss
+5.7%
Price Before
$20.32
Price After
$20.80
Avg Beat Reaction-2.57%
Avg Miss Reaction-0.98%
Beat Rate6 / 8 quarters
Largest Move-9.48% (Q2 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: ACET ends December
Adicet Bio, Inc. (ACET) most recently reported earnings on May 13, 2026 for Q2 FY2026, posting EPS of $-1.88 — beating the analyst consensus of $-2.93 by +35.8%. ACET has beaten EPS estimates for 2 consecutive quarters. The next ACET earnings date is expected around September 1, 2026.
Each quarter, investors track ACET earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. ACET revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
ACET's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
ACET earnings · 5 questionsAdicet Bio, Inc.'s next earnings report is expected around September 1, 2026. ACET typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; ACET historically reports after market close (AMC).
ACET earnings datewhen is ACET earningsACET next earnings datewhen does ACET report earningsACET earnings calendar
▸ Source: FMP · Adicet Bio, Inc. SEC filings · US GAAP · Adicet Bio, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026